Microba Divests Research Unit to Focus on Core Business

Microba Life Sciences Limited (AU:MAP) has released an update.

Microba Life Sciences Limited has strategically transferred its non-core Research Services unit to Denmark’s Clinical Microbiomics A/S, allowing Microba to fully focus on its core diagnostic microbiome testing business. This deal, which includes revenue and commission payments potentially totaling up to $3 million over the next four years, aligns with both companies’ strategies and is expected to bolster shareholder value. Microba retains all its intellectual property and will continue to innovate in its main microbiome analysis and therapeutics sectors.

For further insights into AU:MAP stock, check out TipRanks’ Stock Analysis page.